Compare Dyne Therapeutics Inc. Common Stock (DYN) vs ProShares UltraPro QQQ ETF (TQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs ProShares UltraPro QQQ ETF — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while ProShares UltraPro QQQ ETF trades at $71.68 (market cap $38.26B). The key difference: ProShares UltraPro QQQ ETF is far larger — about 13.4× Dyne Therapeutics Inc. Common Stock's market cap, and ProShares UltraPro QQQ ETF is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and ProShares UltraPro QQQ ETF for 25 Days on average.
| DYN | TQQQ | |
|---|---|---|
Market Cap | $2.86B | $38.26B |
Volume | 3,341,579 | 38,965,303 |
Sector | Health | Leveraged / Inverse |
52-Week High | $26.78 | $87.22 |
52-Week Low | $14.60 | $37.89 |
Typical Hold Time | 0 Days | 25 Days |
Enterprise Value | $2.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
TQQQ trades at $78.81, down 1.0% on the day, with a bullish technical signal from moving averages but neutral oscillators. The leveraged ETF faces mixed sentiment with recent articles highlighting both strong performance during the AI boom and concerns about hidden costs and volatility decay. Support levels are established at $77-$79, with resistance at $81-$82.
The outlook remains volatile with 3x leverage amplifying both gains and losses. Key risks include expense ratios beyond the stated 0.82% and market volatility amplification. Institutional activity shows mixed positioning, with some firms reducing stakes while others add exposure to tech and AI themes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About ProShares UltraPro QQQ ETF
TQQQ is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq-100 Index. It is one of the most liquid and actively traded instruments in the market, designed for sophisticated traders to amplify short-term bullish exposure to large-cap non-financial growth stocks, predominantly in the technology and communication sectors.
Read more on TQQQ →
